The FDA has accepted and granted Priority Review to an application for lower doses of leniolisib to treat younger children with activated phosphoinositide 3-kinase delta syndrome.

The intravenous immune globulin replacement therapy is currently being evaluated in a phase 3 clinical trial assessing motor function and mobility in adult patients with stiff person syndrome.

Approval is supported by phase 3 INShore trial data demonstrating 95% sustained complete remission at 52 weeks with obinutuzumab compared with 73% with MMF.

HealthDay News — Nutritional deficiencies are a common and underrecognized risk among pediatric patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment, according to a study ...

Routine FDA testing found patulin above safety limits in Wholesome Pantry jars sold at ShopRite and four other chains ...

The FDA approved Bravnetsa as the first radioligand therapy through the Abbreviated New Drug Application pathway, offering a bioequivalent alternative to Lutathera for adult patients with ...

Eleven-point-four percent of patients who underwent liver transplantation for cirrhosis developed cirrhosis subsequent to transplant.

HealthDay News — For patients receiving immune checkpoint inhibitors (ICIs), rheumatic immune-related adverse events (rh-irAEs) are usually moderate or severe, with more than one-third leading to ...

Topline phase 3 findings show the KIT receptor inhibitor barzolvolimab significantly reduced itch and hives while achieving high complete response rates in patients with chronic spontaneous urticaria.

Lyrfigtu (lirafugratinib) is approved for previously treated, unresectable, or metastatic FGFR2-altered cholangiocarcinoma based on data from the ReFocus trial.

Probiotic supplement use has surged in the United States, while the consumption of microbiome-supportive foods has remained unchanged, according to a study publ ...

Charles Bonnet syndrome affects about 1 in 6 people with serious vision loss, and experts say talking about it early eases fear ...